跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RYBREVANT 2240 MG SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
RYBREVANT 2240 MG SOLUCION INYECTABLE
Approved
STANDARD
RYBREVANT 2240 MG SOLUCION INYECTABLE
Janssen-Cilag International N.V
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Apr 14, 2025
Approval ID
87a9bb14789dc8be
Company
Janssen-Cilag International N.V
Type
Standard
Approval Details
Approval Id
87a9bb14789dc8be
Drug Cima Aemps Name
RYBREVANT 2240 MG SOLUCION INYECTABLE
Register Number
1211594003
Holder Company Name
Janssen-Cilag International N.V
Marketing Company Name
Janssen Cilag S.A.
Holder Company Detail Path
/organization/janssen-cilag-international-nv
Authorization Date
2025-04-14
Dosage Form
SOLUCIÓN INYECTABLE
Dose
160 mg/ml
Route Of Administration
VÍA SUBCUTÁNEA
Prescription Type
Uso Hospitalario
Commercialized
Yes
Company Name
Janssen-Cilag International N.V
Company Detail Path
/organization/janssen-cilag-international-nv
Company Information
Pharmaceutical Company Name
Janssen-Cilag International NV
Country Name
Belgium
Active Ingredients
AMIVANTAMAB
2240 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Apr 14, 2025
Approval ID
87a9bb14789dc8be
Type
Standard
Back to CIMA-AEMPS Approvals